FrostPharma organisation announcement

During her tenure as CEO for FrostPharma AB, Cecilia Bröms-Thell has invested and prepared the FrostPharma business for accelerated growth while securing solid performance of the in-line portfolio. The Regulatory framework and the Commercial capabilities have been strengthened and FrostPharma is now in a position to leverage and maximise its pipe-line opportunities. Cecilia Bröms-Thell has however recently decided to explore new opportunities outside of FrostPharma why she has resigned as CEO. For a period of time Cecilia has however agreed to stay on as Chief Commercial Officer effective 1 january 2022. In this new role Cecilia Bröms-Thell will continue to strengthen the FrostPharma capabilities. “On behalf of FrostPharma and the Board I want to thank Cecilia Bröms-Thell for her significant contribution to the FrostPharma business as CEO and wish her good luck in her new role within FrostPharma as Chief Commercial Officer and later in her new role outside of Frost.” From the 1st of January 2022 Fredrik Andersch take the role of FrostPharma CEO. Fredrik Andersch brings extensive international experience to FrostPharma from senior business positions at pharmaceutical companies such as AstraZeneca and Meda. Fredrik Andersch has a proven track-record of delivering strong growth through complex organisations both in a Nordic and international setting, such as Europe and Asia. With his background Fredrik Andersch also strengthen FrostPharma business development capabilities. The experience to drive growth through both portfolio and geographic expansion will further strengthen FrostPharma in its growth journey. As Fredrik consulted for FrostPharma in 2021 he has in-depth understanding of the organisation and business model, which secure business continuity during the transition. “On behalf of FrostPharma and the Board I want to wish Fredrik Andersch good luck in his role of CEO, and I look forward to working with him going forward.” About Frost Pharma AB FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence. Tomas Guinchard Chairman of the Board

FrostPharma wins two national tenders in Norway

FrostPharma is proud and pleased to announce that the company has been successful in the tender bidding process in Norway. The company has been notified of winning two national tender contracts in two different therapeutic areas, starting Feb 1, 2022 and running for two years with option to prolong another two years. This means that the health care providers and patients eligible for these specific treatments will have access to our value-added products throughout the tender contract period in Norway. The therapeutic areas in scope for these two treatments are sedation and anti-thrombotic treatment.

ExCEEd Orphan s.r.o. announces joining Your Pharma Partner in Europe network as of May 1, 2021

ExCEEd Orphan s.r.o. (www.exceedorphan.com), are a Czech-based full business solution provider for Biotechnology and Pharmaceutical companies who are launching their products in Central & Eastern Europe. They proudly announce joining the exclusive network of Your Pharma Partner in Europe (www.yourpharmapartner.eu) as of May 1st, 2021. This exclusive network was established in 2012 by two founding partner companies FrostPharma AB based in Sweden (www.frostpharma.com and TwinPharma B.V. based in Netherlands (www.twinpharma.com). With the addition of 14 countries in Central & Eastern Europe covered by ExCEEd Orphan, this network is now able to provide services and deliver innovative treatments to patients in 25 European countries that have a population totaling 180 million. All three partner companies agreed to offer jointly their services to Biotechnology and Pharmaceutical companies looking for partners in Nordics & Baltics, BeNeLux and CEE regions: however, they remain as independent contracting, financing, and business operations.

Jiri Hermanek, CEO and Founding Partner of ExCEEd Orphan s.r.o comments: “We are very proud to join such an exclusive network covering 40% of the European population! We are looking forward to working in partnership with Frost Pharma AB and TwinPharma B.V. to bring innovative medicines to patients in CEE countries.”

Cecilia Bröms-Thell, CEO of FrostPharma AB comments: “We at FrostPharma welcome ExCEEd Orphan s.r.o. to our joint partnership network! Their expertise and knowledge of marketing and sales in the CEE region will enable us to extend our offerings to additional clients interested to launch their products in this important territory.”

Gert van Alewijk, Founding Partner of TwinPharma B.V. adds: “We at TwinPharma are excited and proud to have ExCEEd Orphan s.r.o. as a new partner in our network. By joining us, we expand our territory to such an extent that we become an even more attractive partner for companies that want to introduce their pharmaceuticals in 25 European countries outside the traditional Big 5.

ExCEEd Orphan s.r.o. was founded in 2018 by 5 rare disease experts from multiple countries. The company is focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field. The portfolio of ExCEEd Orphan s.r.o. includes products in therapeutic areas such as hematology, neurology, immunology, and metabolic diseases.

FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence.

TwinPharma B.V. was founded in 2006 by two experienced Pharma industry professionals Gert van Alewijk and Bauke Buwalda in Netherlands. With TwinPharma, they want to contribute to improving healthcare by making available medicines that were previously not available in the region. The company is focusing on innovative treatments and is currently active in several disease areas such as immunology, hepatology, organ transplant and urology.

For further information, please refer to:

www.yourpharmapartner.eu www.exceedorphan.com

www.frostpharma.com

www.twinpharma.com